tbuckley/cabot-search huggingface dataset:
Medical Pronunciation
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fuss und Bein: Ihre Erkrankungen und deren Behandlung. Ein Lehrbuch
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Journal: JNCI Journal of the National Cancer Institute (1989)

Dr. Owen S. Weislow regrets to inform the readers of two errors in a table in his article (J Natl Cancer Inst 81:577ndash;586, 1989). In table 2, the values for the EC50 of the drug DDA in MT-2 and CEM-SS cells should be 0.00175 and 0.00161 μM, respectively.
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
Authors: Anita Y.M. Kwan, Hertzel C. Gerstein, Jan Basile, Denis Xavier, Juan M. Maldonado, Sohini Raha, Manige Konig
Journal: Diabetes Care (2022)

OBJECTIVE To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA1c) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial. RESEARCH DESIGN AND METHODS Change from baseline in HbA1c was assessed during and up to 72 months of treatment before and after adjustment for duration of diabetes, prior microvascular disease (nephropathy or retinopathy), and BMI. Slope analyses were used to assess the change in HbA1c during 0–12 months and 12–72 months of therapy. RESULTS HbA1c was significantly reduced in patients treated with dulaglutide compared with placebo during 72 months of treatment (least-squares mean difference = −0.61%, P &amp;lt; 0.001), regardless of diabetes duration, prior microvascular disease, and BMI (all interaction P &amp;gt; 0.07). Significant reductions were apparent at all time points and were independent of these baseline characteristics. Slope analyses revealed that the dulaglutide group experienced a higher rate of HbA1c reduction compared with the placebo group from 0 to 12 months before and after adjustment. The dulaglutide group also experienced a higher rate of HbA1c increase from 12 to 72 months compared with the placebo group that became nonsignificant after adjustment for diabetes duration, prior microvascular disease, and BMI combined. Despite the greater rate of HbA1c increase in the dulaglutide group during this period, mean HbA1c values remained below baseline in the dulaglutide group and below mean HbA1c values in the placebo group. CONCLUSIONS Dulaglutide 1.5-mg treatment was statistically associated with a long-lasting decrease in HbA1c over 72 months, irrespective of baseline duration of diabetes, microvascular disease, and BMI.
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology
Authors: No-Joon Song, Carter Allen, Anna E. Vilgelm, Brian P. Riesenberg, Kevin P. Weller, Kelsi Reynolds, Karthik B. Chakravarthy, Amrendra Kumar, Aastha Khatiwada, Zequn Sun, Anjun Ma, Yuzhou Chang, Mohamed Yusuf, Anqi Li, Cong Zeng, John P. Evans, Donna Bucci, Manuja Gunasena, Menglin Xu, Namal P. M. Liyanage, Chelsea Bolyard, Maria Velegraki, Shan-Lu Liu, Qin Ma, Martin Devenport, Yang Liu, Pan Zheng, Carlos D. Malvestutto, Dongjun Chung, Zihai Li
Journal: Journal of Hematology & Oncology (2022)

Abstract Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) through direct lysis of infected lung epithelial cells, which releases damage-associated molecular patterns and induces a pro-inflammatory cytokine milieu causing systemic inflammation. Anti-viral and anti-inflammatory agents have shown limited therapeutic efficacy. Soluble CD24 (CD24Fc) blunts the broad inflammatory response induced by damage-associated molecular patterns via binding to extracellular high mobility group box 1 and heat shock proteins, as well as regulating the downstream Siglec10-Src homology 2 domain–containing phosphatase 1 pathway. A recent randomized phase III trial evaluating CD24Fc for patients with severe COVID-19 (SAC-COVID; NCT04317040) demonstrated encouraging clinical efficacy. Methods Using a systems analytical approach, we studied peripheral blood samples obtained from patients enrolled at a single institution in the SAC-COVID trial to discern the impact of CD24Fc treatment on immune homeostasis. We performed high dimensional spectral flow cytometry and measured the levels of a broad array of cytokines and chemokines to discern the impact of CD24Fc treatment on immune homeostasis in patients with COVID-19. Results Twenty-two patients were enrolled, and the clinical characteristics from the CD24Fc vs. placebo groups were matched. Using high-content spectral flow cytometry and network-level analysis, we found that patients with severe COVID-19 had systemic hyper-activation of multiple cellular compartments, including CD8 + T cells, CD4 + T cells, and CD56 + natural killer cells. Treatment with CD24Fc blunted this systemic inflammation, inducing a return to homeostasis in NK and T cells without compromising the anti-Spike protein antibody response. CD24Fc significantly attenuated the systemic cytokine response and diminished the cytokine coexpression and network connectivity linked with COVID-19 severity and pathogenesis. Conclusions Our data demonstrate that CD24Fc rapidly down-modulates systemic inflammation and restores immune homeostasis in SARS-CoV-2-infected individuals, supporting further development of CD24Fc as a novel therapeutic against severe COVID-19.
The current landscape of immunotherapy for pediatric brain tumors
Authors: Eugene I. Hwang, Elias J. Sayour, Catherine T. Flores, Gerald Grant, Robert Wechsler-Reya, Lan B. Hoang-Minh, Mark W. Kieran, Joanne Salcido, Robert M. Prins, John W. Figg, Michael Platten, Kate M. Candelario, Paul G. Hale, Jason E. Blatt, Lance S. Governale, Hideho Okada, Duane A. Mitchell, Ian F. Pollack
Journal: Nature Cancer (2022)
Comparison of myocardial strain rate imaging and triggered myocardial contrast echocardiography to detect the culprit vessel and for the diagnosis of severe coronary artery disease Marcelo Carneiro, Michael L. Lieber, Shashidhar Sathyanarayana, Jill Odabashian, Jeanne Drinko, Jing P. Sun, Christine Whitman, Susan Jasper, Annitta Morehead, Allan L. Klein. The Cleveland Clinic Foundation, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)
Effect of structural heart disease on the long-term efficacy and safety of the metrix implantable atrial defibrillator Hung-Fat Tse, Chu-Pak Lau, Luz-Maria Rodriguez, Carl Timmermans, Emile G Daoud, Gregory M Ayers, Hein J J Wellens. University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Journal: Journal of the American College of Cardiology (2001)
Directional coronary atherectomy in unprotected left main coronary artery: Initial and long-term results of 101 procedures Kunihiko Kosuga, Hideo Tamai, Eisho Kyo, Tatsuhiko Hata, Masaharu Okada, Takuji Nakamura, Hidenori Komori, Takafumi Tsuji, Shinsaku Takeda, Seiichiro Motohara, Hiromu Uehata. Shiga Medical Center for Adults, Moriyama, Japan
Journal: Journal of the American College of Cardiology (2001)
Immunization
Authors: W. Michael McDonnell
Journal: JAMA (1997)

Immunization is undergoing important changes, with improved vaccines replacing less immunogenic or less safe vaccines, new vaccines for common diseases such as chickenpox and hepatitis A infection, and improved immunization schedules. Immunization is also being transformed by basic work in molecular medicine. Vaccines made of DNA are being developed as a form of gene therapy that use the patient's own cellular machinery to make foreign proteins that stimulate an immune response. Currently immunization is used to protect patients prior to exposure to an infectious agent or during the incubation phase after exposure, but before disease has occurred. New technologies are being investigated to induce the immune system to fight infections that have already produced chronic disease such as acquired immunodeficiency syndrome and chronic hepatitis B virus infection.
The effect of left atrial appendage ligation during valvular surgery on thromboembolic events Nour M. Juratli, Mina K. Chung, Delos M. Cosgrove, Bruce W. Lytle, Patrick J. Tchou, Bruce L. Wilkoff, Walid Saliba, Fred J. Jaeger, Robert A. Schweikert, Luther T. Clark, Mark J. Niebauer, Andrea Natale. Cleveland Clinic Foundation, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)
Combining the quantitative fecal immunochemical test and full blood count to rule out colorectal cancer in a symptomatic patient referral pathway.
Authors: Mark Johnstone, Paul Burton, Georgios Kourounis, Jack Winter, Emilia M. Crighton, David Mansouri, Paul Witherspoon, Karen Smith, Stephen Thomas McSorley
Journal: Journal of Clinical Oncology (2022)

28 Background: The faecal immunochemical test (FIT) has proven utility for colorectal cancer (CRC) detection in symptomatic patients. Most studies have examined FIT in symptomatic patients subsequently referred from primary care. We investigated associations between CRC and FIT in both referred and non-referred symptomatic patients. Methods: A retrospective, observational study of all patients with a FIT submitted Aug’18-Jan’19 in NHS GG&amp;C was performed. Referral to colorectal/gastroenterology and decision to perform colonoscopy were recorded. FIT results were grouped as f-Hb&lt;10/10-149/150-399/≥400ug/g. The MCN cancer registry identified new cases of CRC. Covariables were compared using the χ 2 test. Multivariate binary logistic regression identified independent predictors of CRC. Results: 4968 patients were included. Raised FIT correlated with decision to refer (p&lt;0.001) and scope (p&lt;0.001). With 23-month median follow-up, 61 patients were diagnosed with CRC. These patients were older (median 69 vs. 59 years, cancer and no cancer respectively, p=0.001), more likely to be male (55.7% vs. 42.1%, p=0.033) and to report rectal bleeding (51.7% vs. 36.1%, p=0.013). FIT (&lt;10 µg/g 8.2% vs. 76.7% and ≥400 µg/g 55.7% vs. 3.8%, p&lt;0.001) and anaemia (45.9% vs. 19.7%, p&lt;0.001) were associated with CRC. On multivariate analysis, age (p=0.023), male sex (p=0.04), FIT (≥400 OR 54.256 (95% CI: 20.683-142.325; p&lt;0.001)) and anaemia (OR 1.956 (1.071-3.574;p=0.029)) independently predicted CRC. 1 patient (0.04%) with a negative FIT and normal haemoglobin had CRC. Conclusions: Referral from primary care and secondary care investigation patterns were influenced by FIT. The combination of normal Hb and f-Hb excluded CRC in 99.96% of cases, providing excellent reassurance to those prioritising access to endoscopy services.
Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis.
Authors: Antonio D'Alessio, Arndt Weinmann, Peter R. Galle, Claudia Angela Maria Fulgenzi, Dominik Bettinger, Bertram Bengsch, Arndt Vogel, Lorenz Balcar, Bernhard Scheiner, Musharraf Navaid, Abdul Rafeh Naqash, Nicola Personeni, Tiziana Pressiani, Rohini Sharma, Matthias Pinter, Alessio Cortellini, Lorenza Rimassa, David James Pinato
Journal: Journal of Clinical Oncology (2022)

393 Background: Atezolizumab plus bevacizumab (A+B) is the new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). No evidence exists as to its use in routine clinical practice in patients (pts) with impaired liver function. Methods: This retrospective, multi-center observational study was conducted across 7 tertiary academic referral centres and collected 64 HCC pts consecutively treated with A+B. Efficacy outcome measures included overall (OS) and progression-free survival (PFS) calculated from time of A+B commencement and overall response rates (ORR) and disease control rates (DCR) defined by Response Evaluation Criteria in Solid Tumors (RECIST, v1.1). Safety outcomes included treatment-related adverse events (trAEs) graded (G) according to CTCAE v5.0. Results: Of 64 eligible pts, 54 had BCLC C stage HCC (84%), secondary to hepatitis C cirrhosis (n = 24; 37%), hepatitis B (n = 10; 16%), and non-viral etiologies (n = 40; 47%). Liver function was classified as Child-Pugh (CP) A in 46 patients (72%), B7 in 7 (11%), B8 in 8 (12%), and B9 in 3 (5%). Patients were of performance status (PS) ECOG 0 (n = 39; 61%) and 1 (n = 25; 39%). Pre-treatment upper-gastrointestinal endoscopy was performed in 44 patients (69%), with gastro-esophageal varices found in 18 pts (40%) and graded as 1 (n = 12, 27%), 2 (n = 4, 9%) and 3 (n = 2, 4%) respectively. After a median follow-up of 6.8 months (m) (95% confidence interval [CI], 5.5-8.0), median OS (mOS) was 11.7m (95% CI, 6.2-17.3) whereas median progression-free survival (mPFS) was 6.97m (95% CI, 2.9-11.0). ORR and DCR were 26% and 62% respectively. TrAEs of any grade were documented in 43 pts (67%): 12 pts (18%) had trAEs of G≥3: 7 (11%) atezolizumab-related and 5 (8%) bevacizumab-related. Toxicity led to treatment discontinuation in 3 pts (5%). Compared to CP-A, CP-B pts achieved shorter OS (11.7m [95% CI, 10.3-13.2] vs 6.5m (95% CI, 3.5-9.5), p = 0.029) and PFS (9.1m [95% CI, 5.4-12.8] vs 2.3m [95% CI, 1.7-2.9], p = 0.001) with no differences in ORR nor in DCR. The rate of trAEs did not significantly differ across CP classes. Median OS was significantly longer in patients achieving a radiologic response (12.7m [95% CI, not reached] vs 11.0m [95% CI, 5.5-16.5], p = 0.04). Presence and grade of varices was not associated to bevacizumab-related trAEs. Conclusions: This study confirms reproducible efficacy and safety of A+B in routine practice. Despite inferior OS and PFS compared to CP-A, A+B was associated with similar tolerability and radiologic response in CP-B patients, warranting prospective evaluation of A+B in this treatment deprived population.
Abstract 411: The Activated Fibroblast Secretome Drives Cardiomyocyte Dedifferentiation in Pulmonary Hypertension-induced Right Ventricular Dysfunction: a Role for Interleukin-1β?
Authors: Danielle R Bruns, Philip D Tatman, Kurt R Stenmark, Peter M Buttrick, Lori A Walker
Journal: Circulation Research (2017)

Chronic exposure to hypobaric hypoxia (HH) causes pulmonary hypertension (PH) and right ventricular (RV) dysfunction, a strong predictor of survival in a variety of clinical contexts. Inflammatory-fibrotic remodeling underlies PH-induced RV dysfunction, a process regulated in part by cardiac fibroblasts (Cfib). In response to insult, Cfib undergo phenotypic changes including hypersecretion of bioactive molecules which may contribute to ventricular dysfunction. We hypothesized that persistent changes in the activated Cfib phenotype would be mediated through DNA methylation and that secretion of signals from the activated Cfib would contribute to cardiomyocyte dysfunction. We tested this hypothesis using RV Cfib derived from the neonatal calf exposed to HH- a novel large animal model with significant resonance with human disease. HH exposure resulted in an epigenetically modified pro-inflammatory Cfib characterized by global DNA hypomethylation, elevated IL-1β signaling, and activation of a myofibroblast phenotype. IL-1β treatment of control Cfib also elicited DNA hypomethylation and phenotype conversion, albeit less robustly than Cfib derived from the HH-exposed RV. Treatment of adult rat ventricular myocytes (ARVM) with conditioned media from HH-derived Cfib caused dedifferentiation of ARVM to a neonatal-like phenotype characterized by activation of the fetal gene program. Immunodepletion of IL-1β from HH conditioned media attenuated expression of fetal genes and myocyte dedifferentiation. However, IL-1β treatment alone was not sufficient to cause dedifferentiation and fetal gene expression, suggesting other secreted (inflammatory) factors contribute to myocyte disarray and dysfunction. Together, these data suggest a key role of the epigenetically modified activated Cfib in the pathogenesis of PH-induced RV dysfunction, mediated in part by IL-1β signaling. Ongoing investigations will identify other pathways of Cfib-mediated ventricular dysfunction to facilitate manipulation of the fibroblast for therapeutic benefit in right heart disease.
Blockade of Interleukin 27 Signaling Attenuates Graft Versus Host Disease By Augmenting CD4+ and CD8+ Regulatory T Cell Reconstitution
Authors: Ludovic Belle, Kimberle A. Agle, Vivian Zhou, Vanessa Yuan, Jie Sun, Nico Ghilardi, Jacques van Snick, William R. Drobyski
Journal: Blood (2015)
Circulation, New York
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan
Authors: Yasushi Shiratori, Shuichiro Shiina, Masatoshi Imamura, Naoya Kato, Fumihiko Kanai, Takahito Okudaira, Takuma Teratani, Gohichi Tohgo, Nobuo Toda, Makoto Ohashi, Keiji Ogura, Yasuro Niwa, Takao Kawabe, Masao Omata
Journal: Hepatology (1995)

Characteristics of 205 consecutive patients with hepatocellular carcinoma (HCC) admitted during 1990 to 1993 have been analyzed from the standpoint of hepatitis viral infection in Japan. Among 205 HCC patients, 71% of the patients showed positivity for hepatic C virus (HCV) antibody alone, 13% showed positivity both for HCV and HBV (HCV/HBV) antibody, 11% demonstrated HBsAg alone, and negativity of both HCV and HBV antibody in 4% only. Positivity to both HCV antibody and HBsAg was demonstrated in 1% only. Mean detection age of HCVAb-positive HCC as well as both HCV/HBV antibody-positive HCC was 62 ± 7 years, in contrast to 52 ± 13 years in HCC with HBsAg ( P &lt; .05). Male-to-female ratio among HCVAb-positive HCC was 3.3:1, in contrast to 5.5:1 among the HCV/HBVAb-positive HCC and 7:1 among HBsAg-positive HCC, but there was no significant difference in the gender distribution between these groups. More than 60% of HCVAb-positive HCC were classified into the stage of Child B and C, whereas 65% of HBsAg-positive HCC was at the stage of Child A. The severity of liver disease was confirmed by liver histology, indicating that more than 70% of the HCVAb-positive HCC and the HCV/HBVAb-positive HCC showed cirrhosis, in contrast to 50% among the HBsAg-positive HCC. Three-year survival rate of HCV Ab-positive HCC and HBV/HCVAb-positive HCC was 68% and 56%, respectively, in contrast to 47% in HBsAg-positive HCC. HCC was found at early stage among the patients receiving periodic medical checkups beforehand, and the prognosis of these HCC patients was significantly better than those who did not receive checkups. From these results, HCV-related HCC occupied over 80% of total HCC in Japan, which are characterized by older age and more severe cirrhosis, as compared with HBsAg-positive HCC. Prognosis of HCV Ab-positive HCC was not significantly better than HBsAg-positive HCC, but the periodical screening naturally improves prognosis because the cases are found usually much earlier (lead time bias) and mostly belong to slow progression type (length bias). (Hepatology 1995; 22:1027-1033.).
Neoadjuvant Immunotherapy in Melanoma – The New Frontier
Authors: Alexander M. Menzies, Richard A. Scolyer, Georgina V. Long
Journal: Clinical Cancer Research (2021)

Neoadjuvant immunotherapy is gathering pace, particularly in melanoma. A recent study of pembrolizumab and HDI not only further supports the safety and activity of neoadjuvant anti-PD-1 based immunotherapy but also highlights neoadjuvant therapy as a solid platform for drug development that is likely to become a standard-of-care in the near future.See related article by Najjar et al., p. 4195.
Tornado-Associated Fatalities—Arkansas, 1997
Journal: JAMA (1997)

On March 1, 1997, approximately nine tornadoes originating from two separate thunderstorms swept across Arkansas, from Hempstead County in the southwest to Clay County in the northeast (approximately 260 miles). The tornadoes caused 26 deaths and an estimated $115 million in property damage, reflecting damage to residences, nonresidential buildings, bridges, and roads and agriculture and timber losses. The strongest tornadoes touched down southwest of Little Rock in Clark, Saline, and Pulaski counties; the estimated widths of the tornado paths ranged from 1/2 to 1 mile, and wind speeds were > 200 miles per hour (National Weather Service [NWS], unpublished data, 1997). This report summarizes circumstances of the tornado-associated fatalities from information collected by the American Red Cross (ARC); 14 of the 26 fatalities occurred among persons who were in mobile homes.